GRADE study evaluates four new medications for Type 2 diabetes

Published on December 31, 2013 at 1:31 AM · 1 Comment

The GRADE study at the University of Alabama at Birmingham had a special visitor in November. Red suit. Black boots. White beard. Belly that shook like a bowl full of jelly. A V.I.E. (Very Important Elf) visited this national clinical trial for Type 2 diabetes.

The GRADE study is evaluating four new medications for Type 2 diabetes. Patient confidentiality issues prohibit UAB from confirming anything about the health status of any patient, including our V.I.E. Suffice it to say that the Big Guy has some risk factors for diabetes.

"He has several risk factors associated with the development of Type 2 diabetes," said Andrea Cherrington, M.D., associate professor of Preventive Medicine in the School of Medicine. "He's overweight, he has a pretty sedentary lifestyle, and he doesn't maintain the healthiest diet. These risk factors are also related to the development of cardiovascular disease, high blood pressure and stroke."

The GRADE study is a large, multisite research effort sponsored by the National Institutes of Health. The primary investigators for the UAB component of the study are Cherrington and W. Timothy Garvey, M.D., professor and chair of the School of Health Professions Department of Nutrition Sciences and director of the UAB Diabetes Research Center.

GRADE is comparing four medications currently being used to treat Type 2 diabetes to be taken in conjunction with metformin, the most established medication used in the majority of diabetes cases.

As the disease progresses, many patients taking metformin eventually require an additional medication to control blood sugar. At present, there is little consensus on which combinations of the current diabetes drugs in conjunction with metformin will best serve different patient populations.

"It's a bit of a guessing game for physicians right now, as we really don't have any good scientific evidence to help guide the decision-making about which combination will be the best regimen for each individual," Cherrington said.

The GRADE study is looking to enroll a cross section of patients with Type 2 diabetes: any age, any gender, any ethnicity. The study will follow its participants for seven years and will provide free medications and diabetes care. Contact Dana Golson at 205-996-4015 or ccnrn@uab.edu for more information on enrolling in the study.

As far as the guy in the red suit is concerned, Cherrington says he needs to be thinking about some lifestyle modification.

"He's overweight, his assistants do most of the physical activity at the workshop, and he's flying around, not walking," said Cherrington. "And then there is the dietary component. Frequent sweets, cookies, high-fat milk — that's pretty much the opposite of what we would recommend for good diabetes prevention or management."

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
  1. Mintas Lanxor Mintas Lanxor United States says:

    Metformin and glimepiride together worked well for me until they lost their efficacy, as diabetes drugs eventually do in most cases. Once you realize that maximum doses of any drugs don't work any more (after a couple of months), don't go to your family doctor. Instead, go to see an endocrinologist and start taking insulin. Family physicians are notoriously cautious in suggesting this at the expense of their patients' health.
    Unless your insurance pays for all of your insulin (and very few do), ask your endocrinologist to put you on the least expensive kind - Novo Nordisk's Relion N, which can be had at Wal Mart for 25 bucks a vial and for even less thru insurance. Endocrinologists like to start you on expensive pen-type injectors, and I suspect there are sweet deals with drug companies involved. I used Lantus Solo Star pen for a year, and it cost me about a $1,000.00 - with insurance! I then asked to be switched to Relion, which I find to be just as good (unlike Eli Lilly's Humulin N) at about the fifth of the Lantus cost.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post